capable of detecting all the major mutations against the antiviral drugs.
5
In this study we analysed the performance characteristics and comparability of Abbott real- systems. The ability to detect antiviral resistant mutants in these systems was also attempted.
13

Materials and Methods
14
Standards
15
The second WHO international standard for HBV DNA (National Institute for Biologicals The QIAamp DNA blood kit uses the silica-membrane technology for purification of DNA. LLD of artus HBV RG PCR using the DSP virus kit was claimed to be 3.8 IU/mL (95% 6 detection limit).
7
Determination of HBV antiviral resistance mutations and genotypes
8
Amplification and sequencing of HBV reverse transcriptase (rt) gene was carried out for 30 9 samples as described earlier (7). HBV genotypes were determined by aligning study 10 sequences with HBV genotype reference sequences. Phylogenetic analysis was performed in 11 MEGA4 using the neighbour-joining method with a bootstrap test of 1000 replicates and 12 maximum composite likelihood algorithm.
13
Serology testing
14
HBsAg testing was performed in EIA (Diasorin S.P.A., Saluggia, Italy) and Axsym (Abbott,
15
Wiesbaden, Germany). HBeAg testing was performed in EIA (Diasorin S.P.A., Saluggia,
16
Italy).
17
All clinical samples and HBV DNA standards were stored in aliquots at -60 o C till testing. 
Results
3
Analytical sensitivity (lower limit of detection) 4 To determine the LLD the WHO standard of HBV DNA (NIBSC) at dilutions 100, 50, 25, 10 5 and 1 IU/mL were tested in quadruplicates in five runs to obtain 20 data points for each 6 dilution. Probit analysis showed the LLD of Abbott, artus-DB and artus-DSP to be 1.43 (CI 7 not determined), 82 (95% CI 56 to 179 IU/mL) and 9 IU/mL (95% CI 5 to 31 IU/mL) 8 respectively (Table 1) . HBV DNA standards at dilutions 100, 50 and 25 IU/mL (2, 1.69897 9 and 1.39794 Log 10 IU/mL) for which quantitative values were available were plotted against respectively. The mean difference for HBV DNA standards 100, 50 and 25 IU/mL were 18.5, 13 14.75 and 9.5 IU/mL for Abbott and 33.8, 12.35 and 5.3 IU/mL for artus-DSP respectively.
14
The correlation of artus-DB for these standard dilutions was poor (r=0.54) with a mean 15 difference of -65.25, -39.68 and -18.78 IU/mL respectively. (Fig.1) 
16
Precision and reproducibility
17
Precision and reproducibility of the assays was evaluated by intra-assay and interassay (13.33%), 2 (6.67%) and 24 (80%) samples respectively. There was a good correlation for
13
HBV DNA levels between the assays irrespective of HBV genotypes (Fig. 4 and 5) . Linear 14 regression analysis was not performed for genotype C as there were only two samples for 15 analysis. However, the Log difference between assays for genotype C ranged between -0.22 16 to 0.5 log 10 IU/mL. (Table 3) 17 Out of these samples two patients on lamivudine and lamivudine adefovir combination were 18 detected with rtM204I mutation and one patient on lamivudine therapy was identified with specificity was not performed as it is required mainly for home-brewed assays (2).
16
Analytical sensitivity determination showed Abbott and artus-DSP real-time systems to 17 detect HBV DNA <10 IU/mL and meet the recommended guidelines for HBV management. reproducibility of results in clinical specimens instead of using standards in different matrix.
10
Comparison of clinical samples showed the Abbott system to be very sensitive detecting 
